Northern Trust
PRME icon

Northern Trust’s Prime Medicine PRME Stock Holding History

Northern Trust’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.37M Buy
912,597
+25,881
+3% +$86K ﹤0.01% 2859
2026
Q1 		$3.09M Buy
886,716
+44,563
+5% +$170K ﹤0.01% 2726
2025
Q4 		$2.92M Buy
842,153
+234,164
+39% +$1.04M ﹤0.01% 2775
2025
Q3 		$3.37M Buy
607,989
+95,755
+19% +$389K ﹤0.01% 2728
2025
Q2 		$1.27M Sell
512,234
-15,075
-3% -$23.2K ﹤0.01% 3258
2025
Q1 		$1.05M Sell
527,309
-17,628
-3% -$45K ﹤0.01% 3251
2024
Q4 		$1.59M Buy
544,937
+20,389
+4% +$71.6K ﹤0.01% 3147
2024
Q3 		$2.03M Buy
524,548
+131,031
+33% +$607K ﹤0.01% 2994
2024
Q2 		$2.02M Buy
393,517
+53,519
+16% +$324K ﹤0.01% 2890
2024
Q1 		$2.38M Sell
339,998
-4,929
-1% -$37.4K ﹤0.01% 2868
2023
Q4 		$3.06M Buy
344,927
+11,969
+4% +$92.2K ﹤0.01% 2763
2023
Q3 		$3.18M Buy
332,958
+50,527
+18% +$656K ﹤0.01% 2687
2023
Q2 		$4.14M Buy
282,431
+192,352
+214% +$2.69M ﹤0.01% 2601
2023
Q1 		$1.11M Buy
90,079
+6,533
+8% +$106K ﹤0.01% 3188
2022
Q4 		$1.55M Buy
+83,546
New +$1.51M ﹤0.01% 3114

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Northern Trust's PRME Position: Q2 2026 in Review

Northern Trust increased its Prime Medicine (PRME) stake by 2.9% in Q2 2026, buying an estimated $86K and bringing the position to 912,597 shares worth $3.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2859.

Northern Trust first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.14M in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Northern Trust held 912,597 shares of Prime Medicine worth $3.37M as of Q2 2026.
  • Northern Trust bought 25,881 Prime Medicine shares in Q2 2026, an estimated $86K.
  • Prime Medicine made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2859 holding.
  • Northern Trust first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Northern Trust's Prime Medicine position peaked at $4.14M in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.